Mondobiotech Holding AG Company presentation
Mondobiotech Holding AG Company presentation
Mondobiotech Holding AG Company presentation
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
mondoBIOTECH’s IP Strategy<br />
Background<br />
• Our medicinal product candidates (MPCs) are already known peptides, whose<br />
properties and mechanisms of actions are described in a large number of publications<br />
(10’000 to 100’000 for each peptide)<br />
• Many of our MPCs have already been on the market for a different indication or were<br />
tested in humans for a different indication<br />
• Peptides with large amount of literature available constitute the universe for our<br />
Search&Match to find a valid match with one or more rare diseases. Such matches are<br />
further analyzed to become a robust MPC in our pipeline<br />
• Peptides with a larger number of information and studies available are the best<br />
candidates for a viable development strategy, where a fast track to market can be<br />
designed for our licensees, both for safety and efficacy profiles<br />
• Each of our MPCs is a product platform which can be re-directed for a variety of new<br />
indications, in rare diseases and potentially in non-rare diseases<br />
30